Printer Friendly

Peregrine Pharmaceuticals signs new research collaboration with National Comprehensive Cancer Network.

M2 EQUITYBITES-January 8, 2016-Peregrine Pharmaceuticals signs new research collaboration with National Comprehensive Cancer Network

(C)2016 M2 COMMUNICATIONS http://www.m2.com

Peregrine Pharmaceuticals, a United States pharmaceutical company, has signed a new research collaboration with the National Comprehensive Cancer Network, a not-for-profit alliance of 26 of the world's cancer centres devoted to patient care, research, and education.

It was reported yesterday that the collaboration is aimed at expanding the firm's ongoing clinical research and development of bavituximab for the treatment of a range of tumours. The product is an investigational immunotherapy designed to assist the body's immune system by targeting and modulating the activity of phosphatidylserine, a highly immune-suppressive signalling molecule expressed broadly on the surface of cells in the tumour microenvironment.

Peregrine Pharmaceuticals will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at National Comprehensive Cancer Network Member Institutions and their affiliate community hospitals through a USD2m research grant to National Comprehensive Cancer Network's Oncology Research Programme. National Comprehensive Cancer Network will be responsible for oversight and monitoring of the clinical studies through the research grant.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jan 8, 2016
Words:193
Previous Article:Vernalis selects Corvus Pharmaceuticals.
Next Article:Tanger announces Q4 2015 dividend of USD0.285 per share.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters